Investigating kidney injury caused by cancer immunotherapy drugs
Official title: Preclinical and Clinical Models of Drug Induced Kidney Injury
Funded at University of Colorado Denver · NIH-10884296 · Data updated 2026-11-12
This study is looking at how certain cancer treatments can sometimes harm the kidneys, and it's for patients who are receiving these therapies; the researchers want to find better ways to spot kidney problems early and figure out who might be more at risk, all to keep patients safer and improve their treatment results.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | July 7, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $596,308 |
| NIH project number | 5R01CA277313-02 |
| Project ID | NIH-10884296 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include cancer patients who are receiving immune checkpoint inhibitors and may be at risk for kidney-related side effects.
✕Less likely to help
Patients who are not undergoing treatment with immune checkpoint inhibitors or those with pre-existing severe kidney conditions may not benefit from this research.
What this research studies
This research focuses on understanding how immune checkpoint inhibitors, which are used to treat cancer, can lead to kidney damage in patients. It aims to develop preclinical models that mimic human immune responses to identify the mechanisms behind this kidney toxicity. By studying these models, researchers hope to improve the detection of kidney injury and predict which patients are at risk. The ultimate goal is to enhance patient safety and treatment outcomes for those receiving these cancer therapies.
Why it matters
Potential benefit: If successful, this research could lead to better monitoring and prevention strategies for kidney damage in cancer patients treated with immunotherapy.
How similar studies have gone: Previous research has shown that understanding immune-related adverse events can lead to improved patient outcomes, indicating that this approach has potential for success.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Joy, Melanie S — University of Colorado Denver
- Study coordinator: Joy, Melanie S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.